Red blood cell precursor mass as an independent determinant of serum erythropoietin level.
Serum erythropoietin (sEpo) concentration is primarily related to the rate of renal production and, under the stimulus of hypoxia, increases exponentially as hemoglobin (Hb) decreases. Additional factors, however, appear to influence sEpo, and in this work, we performed studies to evaluate the role of the red blood cell precursor mass. We first compared the relationship of sEpo with Hb in patients with low versus high erythroid activity. The first group included 27 patients with erythroid aplasia or hypoplasia having serum transferrin receptor (sTfR) levels < 3 mg/L (erythroid activity < 0.6 times normal), while the second one included 28 patients with beta-thalassemia intermedia having sTfR levels > 10 mg/L (erythroid activity > 2 times normal). There was no difference between the two groups with respect to Hb (8.3 +/- 1.6 v 8.0 +/- 1.3 g/dL, P > .05), but sEpo levels were notably higher in patients with low erythroid activity (1,601 +/- 1,542 v 235 +/- 143 mU/mL, P < . 001). In fact, multivariate analysis of variance (ANOVA) showed that, at any given Hb level, sEpo was higher in patients with low erythroid activity (P < .0001). Twenty patients undergoing allogeneic or autologous bone marrow transplantation (BMT) were then investigated. A marked increase in sEpo was seen in all cases at the time of marrow aplasia, disproportionately high when compared with the small decrease in Hb level. Sequential studies were also performed in five patients with iron deficiency anemia undergoing intravenous (IV) iron therapy. Within 24 to 72 hours after starting iron treatment, marked decreases in sEpo (up to one log magnitude) were found before any change in Hb level. Similar observations were made in patients with megaloblastic anemia and in a case of pure red blood cell aplasia. These findings point to an inverse relationship between red blood cell precursor mass and sEpo: at any given Hb level, the higher the number of red blood cell precursors, the lower the sEpo concentration. The most likely explanation for this is that sEpo levels are regulated not only by the rate of renal production, but also by the rate of utilization by erythroid cells.
Cazzola
M
M
Department of Internal Medicine and Medical Therapy, Section of Internal Medicine and Medical Oncology, University of Liege, Liege, Belgium.
Guarnone
R
R
Cerani
P
P
Centenara
E
E
Rovati
A
A
Beguin
Y
Y
D000740:Anemia / Q000097:blood*; D000741:Anemia, Aplastic / Q000097:blood; D000747:Anemia, Hypochromic / Q000097:blood / Q000188:drug therapy; D000749:Anemia, Megaloblastic / Q000097:blood; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D004909:Erythrocyte Indices; D015672:Erythroid Precursor Cells; D004920:Erythropoiesis; D004921:Erythropoietin / Q000096:biosynthesis / Q000097:blood*; D005246:Feedback; D005492:Folic Acid / Q000627:therapeutic use; D006689:Hodgkin Disease / Q000097:blood / Q000188:drug therapy; D006801:Humans; D007501:Iron / Q000627:therapeutic use; D007668:Kidney / Q000378:metabolism; D011990:Receptors, Transferrin / Q000032:analysis; D019172:Transplantation Conditioning; D014805:Vitamin B 12 / Q000627:therapeutic use; D017086:beta-Thalassemia / Q000097:blood
D011990:Receptors, Transferrin; D004921:Erythropoietin; D005492:Folic Acid; D007501:Iron; D014805:Vitamin B 12